期刊文献+

2种新型基因工程长效人胰岛素类似物 被引量:18

Two novel long acting human insulin analogs produced by genetic engineering
下载PDF
导出
摘要 甘精胰岛素和地特胰岛素是2种新型的人胰岛素类似物。虽然他们都通过基因工程的方法生产,药效能持续24h,无明显的波峰和波谷,是真正意义上的基础胰岛素,但是这2种长效胰岛素的分子结构、长效机制、生产工艺各不相同,在临床使用上也有各自的利弊。 Insulin glargine and insulin detemir are both of human insulin analogs, produced through genetic research engineering. They are both basal insulins; because of they can remaining active for a full 24 hours with essentially no peaks or valleys, but having different molecular structure, long acting mechanisms, artworks and different clinical effects.
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2007年第7期548-552,共5页 Chinese Journal of New Drugs and Clinical Remedies
关键词 甘精胰岛素 地特胰岛素 糖尿病 insulin glargine insulin detemir diabetes mellitus
  • 相关文献

参考文献21

  • 1BETHEL MA,FEINGLOS MN.Basal insulin therapy in type 2 diabetes[J].J Am Board Fam Pract,2005,18(3):199-204.
  • 2VAJO Z,FAWCETT J,DUCKWORTH WC.Recombinant DNA technology in the treatment of diabetes:insulin analogs[J].Endocr Rev,2001,22(5):706-717.
  • 3HEINEMANN L,LINKESCHOVA R,RAVE K,et al.Timeaction profile of the long-acting insulin analog insulin glargine (HOE901)in comparison with those of NPH insulin and placebo[J].Diabetes Care,2000,23(5):644-649.
  • 4BIRKELAND KI.Clinical use of long-acting insulin analogs[J].Tidsskr Nor Laegeforen,2006,126(8):1067-1068.
  • 5MICHAEL D.A21,B30,modified insulin derivatives having an altered action profile:USP,6100376[P].1997.
  • 6ROSENSTOCK J,PARK G,ZIMMERMAN J.Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens[J].Diabetes Care,2000,23(8):1137-1142.
  • 7SORAN H,YOUNIS N.Insulin detemir:a new basal insulin analogne[J].Diabetes Obes Metab,2006,8(1):26-30.
  • 8冯佑民,张友尚.重组人胰岛素研究的回顾和展望[J].生物工程进展,1996,16(4):26-31. 被引量:7
  • 9McKEAGE K,GOA KL.Spotlight on insulin glargine in type 1 and 2 diabetes mellitus[J].Treat Endocrinol,2002,1(1):55-58.
  • 10KURTZHALS P,SCHAFFER L,SORENSEN A,et al.Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use[J].Diabetes,2000,49(6):999-1005.

二级参考文献11

  • 1卜石,邢小燕,王娜,赵文惠,杨文英.长效胰岛素联合口服降糖药治疗2型糖尿病的疗效与安全性[J].中国循证医学杂志,2004,4(7):464-467. 被引量:157
  • 2Chan S J,Proc Natl Acad Sci USA,1981年,78卷,5401页
  • 3张友尚,中国科学
  • 4张保焰,中国系列化学会第五次基因结构、克隆与调控学术讨论会,1993年
  • 5STRATTON IM,ADLER AI,NEIL HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS35) :prospective observational studyIJ]. BMJ,2000,321(7258):405-412.
  • 6KLEIN R, KLEIN BE,MOSS SE. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus [J]. Ann Intern Med, 1996, 124(1 Pt 2):90-96.
  • 7RILEY MD, BLIZZARD L. Comparative validity of a food frequency questionnaire for adults with IDDM (UKPDS16)[J]. Diabetes Care, 1995,18(9) : 1249-1254.
  • 8TURNER RC,CULL CA,FRIGHI V ,et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus:progressive requirement for multiple therapies(UKPDS49)[J]. JAMA, 1999, 281(21):2005-2012.
  • 9MATTHAEI S, STUMVOLL M, KELLERER M, et al. Pathophysiology and pharmacological treatment of insulin resistance[J],Endocr Rev, 2000,21 (6) : 585-618.
  • 10YKI-JARVINEN H,DRESSLER A,ZIEMEN M, et al. Less nocturnal hypoglycemia and better post dinner glucose control with bedtime insulin glargine compared with bedtime NPN insulin during insulin combination therapy in type 2 diabetes [J]. Diabetes Care, 2000,23 (8) : 1130-1136.

共引文献13

同被引文献132

引证文献18

二级引证文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部